Haibo Zhang

Cardiac surgeon
Beijing Anzhen Hospital, Tongzhou - beijing, China

Latest contributions

Bicuspid and complications

09 Feb 2025 – From PCR Tokyo Valves 2025

Delve into this comprehensive session exploring the complexities of bicuspid aortic valve disease and the associated complications. Discover tailored sizing techniques for balloon-expandable valves in type 1 bicuspid, navigate the challenges of TAVR in bicuspid aortic valve type 0 with small annulus and coronary compromise, and...

Bicuspid and complications

Hot topics in TAVI

09 Feb 2025 – From PCR Tokyo Valves 2025

Explore the latest hot topics in TAVI, including the impact of balloon-expandable TAVR valve deformation and calcium distribution on outcomes in bicuspid aortic valve, the outcomes of complex and high-risk vs. standard PCI in TAVI patients, hemodynamic outcomes after TAVI for aortic stenosis with small annuli,...

Hot topics in TAVI

High-risk TAVI

08 Feb 2025 – From PCR Tokyo Valves 2025

Delve into the management of high-risk TAVI cases in this session. Discover innovative approaches, such as Impella-assisted TAVI in severe bicuspid aortic valve disease with severe left ventricular dysfunction, TAVR for pure native aortic regurgitation in surgically unfit patients, and the use of TAVI as a...

High-risk TAVI

TAVI complications cases: acute decompensated HF, LV perforation & more

08 Feb 2025 – From PCR Tokyo Valves 2025

Delve into this session to explore a range of complex TAVI complication cases. From severe aortic stenosis with left main coronary artery dissection and severe primary MR, to stuck commissural tabs, acute left ventricular perforation, and more - gain insights on how to effectively manage these...

TAVI complications cases: acute decompensated HF, LV perforation & more

Learn the evidence - Lifetime management of aortic stenosis therapy with self-expandable valve

17 Feb 2024 – From PCR Tokyo Valves 2024

In this dedicated session on aortic stenosis management, gain insights into interpreting the 10-year outcomes of the NOTION trial, the 4-year outcomes of the Evolut Low Risk trial, and the key findings from the CANNULATE TAVR study, and discuss the issue of long-term device durability, draw comparisons...

Learn the evidence - Lifetime management of aortic stenosis therapy with self-expandable valve